FDA Weed Meds Get Federal Green Light: Faster Permits for Businesses
Published Date: 4/28/2026
Rule
Summary
Starting April 28, 2026, FDA-approved marijuana-based medicines move from the strictest drug category (Schedule I) to a less strict one (Schedule III). This change helps medical marijuana businesses get faster federal permits to make and sell these products legally. If you have a state medical marijuana license, you’ll find it easier and quicker to work with these medicines under new federal rules.
Analyzed Economic Effects
7 provisions identified: 3 benefits, 4 costs, 0 mixed.
Section 280E Deduction Disallowance Ends for Licensees
As a result of the rescheduling, state medical marijuana licensees will no longer be subject to the deduction disallowance in Internal Revenue Code Section 280E, which applies only to businesses trafficking in Schedule I or II substances. The rule notes businesses should consult tax counsel and that the rule itself does not make a federal tax‑liability determination.
FDA‑approved Marijuana Moved to Schedule III
Effective April 28, 2026, drug products containing marijuana that have been approved by the Food and Drug Administration and marijuana covered by a state medical marijuana license are placed in Schedule III of the Controlled Substances Act. This change applies specifically to marijuana as defined in the CSA when included in an FDA‑approved drug product or when subject to a state medical marijuana license.
Expedited Federal Registration for State Licensees
The rule creates an expedited DEA registration pathway for entities holding state medical marijuana licenses so they can manufacture, distribute, or dispense under federal law; applicants who apply within 60 days of publication must be processed within six months, and early applicants may lawfully operate under their state-issued licenses while DEA reviews their application. A DEA registration will automatically suspend if the underlying state license is suspended, revoked, or expires.
DEA Registration, Compliance, And Fees Required
Anyone handling FDA‑approved drug products containing marijuana must obtain DEA registration for Schedule III activities and comply with inventory, recordkeeping, security, labeling, disposal, and reporting rules. Except for government employees, applicants must pay registration fees: Manufacturers $3,699 annually; Distributors $1,850 annually; Dispensers (including pharmacies) $888 for a registration valid for 3 years.
Unlicensed Bulk Marijuana Still Schedule I
Marijuana that is not in an FDA‑approved drug product and not subject to a state medical marijuana license (including unlicensed bulk marijuana, marijuana extract, and Delta‑9‑THC material used to make FDA‑approved products) remains a Schedule I controlled substance and continues to be subject to quota requirements and DEA purchase/wholesale‑monopoly procedures.
Import/Export Permits Remain Required
The rule adds FDA‑approved drug products containing marijuana and state‑licensed medical marijuana to the list of nonnarcotic Schedule III–V substances that require a DEA import or export permit under 21 CFR 1312.30. Importations and exportations of these covered products will be permitted only pursuant to a permit.
Prescription Requirement for Dispensing
Prescriptions are required before dispensing FDA‑approved drug products containing marijuana except when the product is dispensed directly by a DEA‑registered practitioner (e.g., physician, dentist, hospital). Prescriptions must include the drug name, strength, dosage form, quantity, directions for use, and be issued for a legitimate medical purpose.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-08172, Magnuson-Stevens Act Provisions; Fisheries of the Northeastern United States; Northeast Multispecies Fishery; Allocation of 2026 Northeast Multispecies Annual Catch Entitlements and Notice of Default Specifications
The 2026 fishing season for Northeast multispecies groundfish is set! Approved fishing groups get their catch limits starting May 1, 2026, so they can keep fishing without a hitch. If new rules don’t come by October 31, some fishing spots will close starting November 1, 2026, to protect fish stocks and keep things fair.
Next: 2026-08191, Amendment of Class E Airspace; Miami, FL
The FAA fixed some airport name mistakes in the Miami airspace rules that were published earlier this year. This update doesn’t change when the rules start (July 9, 2026) or cost anything but makes sure pilots and controllers have the right info. If you fly or work near Miami airports, this correction keeps everything clear and safe.